Witryna21 wrz 2024 · Heart problems: Sumatriptan works by constricting blood vessels, so it may not be suitable for people with heart conditions. Sumatriptan can worsen coronary artery disease (ischemia) or provoke a heart attack (myocardial infarction) or Printzmetal’s angina (coronary artery vasospasm). It can also cause irregular heart … Witryna12 sie 2024 · Warnings. You should not use sumatriptan if you have ever had heart disease, coronary artery disease, blood circulation problems, Wolff-Parkinson-White syndrome, uncontrolled high blood pressure, severe liver disease, a heart attack or stroke, or if your headache seems to be different from your usual migraine …
Reference ID: 4194797 - Food and Drug Administration
Witryna1 lut 2011 · Ibuprofen at standard doses is effective for acute migraine treatment. A. 21. Intravenous metoclopramide (Reglan) is effective for acute migraine treatment. B. 11. Parenteral dexamethasone is ... Witryna15 gru 2011 · These drugs, including Amerge® (naratriptan), Axert®, Frova®, Imitrex® (sumatriptan), Maxalt®, Relpax®, Treximet® and Zomig®, are sometimes the only medications that will work for migraine sufferers, but because they narrow blood vessels by 10 to 20%, they are contraindicated with certain types of heart disease. Stewart … clarins lip milky mousse 03
Imitrex: Package Insert - Drugs.com
Witryna• History of coronary artery disease or coronary artery vasospasm (4) • Wolff-Parkinson-White syndrome or other cardiac accessory conduction ... perform a cardiac evaluation if these patients are at high cardiac risk. The use of IMITREX nasal spray is contraindicated in patients with CAD and those with Prinzmetal’s variant angina. 5.4 . Witryna17 wrz 2024 · Triptans are contraindicated in patients with ischemic heart disease because of concerns about vasospasm of coronary vessels that could lead to myocardial ischemia. WitrynaIntroduction. Heart failure (HF) remains the leading discharge diagnosis among patients ≥65 years of age. The estimated cost for treatment of HF in Medicare recipients is $31 billion and is expected to increase to $53 billion by 2030. 1 Hospitalization for HF is the largest segment of those costs. It is likely that the prevention of drug-drug interactions … clarins lifting serum